Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2001

View Archived Issues

NIH technology available for licensing: antiprogestins with partial agonist activity

Alizyme: clinical and preclinical development program update

Update of Pozen's clinical drug candidates for migraine

ProstaRex shows broad T-cell response in preclinical prostate cancer studies

AeroGen reports product update

Boehringer Ingelheim prepares large international study for prevention of cardiovascular disease

OSI begins first in series of OSI-774 trials in combination with anticancer agents

Microsphere formulation of KNI-272 tested in HIV-infected patients

Alliance plans to continue development of Oxygent

Cumulative neuromuscular toxicity is dose-limiting for LU-79553

Positive results reported from phase III trial of Novavax's Estrasorb; NDA in preparation

Millennium gains rights to PDL's antibody humanization patents

Controlled trial examines efficacy of embryonic dopamine neuron transplantation in PD

Nastech's nasal triptan enters phase I for migraine pain

Gastrointestinal and colonic prokinetic effects of prucalopride confirmed in constipated patients

Morphochem/Sosei collaboration will optimize anticancer telomerase inhibitor

Tibotec and Virco merger complete

Company Profile: Speedel

SB-273005, an orally active vitronectin receptor antagonist with disease-modifying properties

Shire seeks E.U. approval of Foznol

New doses of Kadian approved in U.S.

Patient enrollment complete in pivotal phase III trial of Xcytrin

Small-molecule inhibitors of cell adhesion in the Boehringer Ingelheim pipeline

Oral prodrugs of immunosuppressive/antiallergic compounds prepared at Shionogi

Shionogi identifies new series inhibiting sPLA2

AHP scientists claim new bicyclic vitronectin antagonists and use in osteoporosis

GlycoTech presents new sialyl-Lewis(a) and sialyl-Lewis(x) analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...